James Drakakis, DO
Nephrology · Mineola, NYNPI 1285915322
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $48 of the $69 with a category attached, or 68.6%. 3 manufacturers reported payments, led by Novartis at 46.5% of the total. 2024 is the largest year on record at $32, 2.1 times the $15 reported in 2019. That places this record below the midpoint for nephrology clinicians in NY, where the typical reported total is $564.
Across 3 payments — averaging $23.12 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$32
- OPKO Pharmaceuticals, LLC$22
- Nxstage Medical, Inc.$15
Across 72 payments — averaging $1458.17 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Akebia Therapeutics Inc$59K
- Bayer$40K
- Otsuka Pharmaceutical Development & Commercialization, Inc.$6K
What the payments were for
- Food & beverage$4869%
- Education$2231%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 1 | $32 |
| OPKO Pharmaceuticals, LLC | 1 | $22 |
| Nxstage Medical, Inc. | 1 | $15 |
How this compares
$69 in reported general payments places this provider in the 15th percentile of 935 nephrology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FarxigaDapagliflozin Propanediol | 157 | $161,071 |
| VeltassaPatiromer Calcium Sorbitex | 50 | $55,149 |
| JanuviaSitagliptin Phosphate | 23 | $31,799 |
| EliquisApixaban | 20 | $28,185 |
| JardianceEmpagliflozin | 16 | $22,731 |
| LokelmaSodium Zirconium Cyclosilicate | 15 | $11,703 |
| Cinacalcet Hcl | 16 | $9,421 |
| Febuxostat | 34 | $9,036 |
| Tacrolimus | 31 | $7,553 |
| Eplerenone | 86 | $7,320 |
| Torsemide | 246 | $6,011 |
| Sevelamer Carbonate | 25 | $5,335 |
| Mycophenolate Mofetil | 15 | $2,787 |
| Losartan Potassium | 183 | $1,746 |
| Valsartan | 62 | $1,618 |
Paid to pharmacies, not to this prescriber.
Other nephrology in Mineola
- Steven FishbaneMineola$207K
- Binny KoshyMineola$170K
- Payam ShakouriPoughkeepsie$930K
- Gerald AppelNew York$842K
- Richard ChanNew York$514K
- Bruce SpinowitzBronx$465K
- Steven CocaNew York$445K
- Joseph RoglieriTroy$425K
- Jai RadhakrishnanNew York$369K
- Savneek ChughHawthorne$325K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.